NVCR Q3 2024 Earnings — NovoCure Limited Revenue & Financial Results | Market Cap Arena

NVCRNovoCure Limited

$1B

Q3 2024 Earnings

Healthcare Medical - Instruments & Supplies

Income Statement

Revenue

$155M+21.8% YoY

Gross Profit

$120M77.2% margin

Operating Income

-$32M-20.7% margin

Net Income

-$31M-19.7% margin

EPS (Diluted)

$-0.28

QoQ Revenue Growth

+3.2%

Cash Flow

Operating Cash Flow

$10M

Free Cash Flow

-$307,000

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$861M

Stockholders' Equity

$361M

Cash & Equivalents

$185M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$155M	$127M	+21.8%
Gross Profit	$120M	$95M	+25.7%
Operating Income	-$32M	-$58M	+44.9%
Net Income	-$31M	-$49M	+38.2%

Geographic Segments

UNITED STATES

$98M50%

International Markets

$52M27%

GERMANY

$17M9%

FRANCE

$15M8%

JAPAN

$9M4%

CHINA

$5M2%